Los Angeles, USA, Sept. 09, 2021 (GLOBE NEWSWIRE) — Chemotherapy-Induced Diarrhea Pipeline Expected to Witness the Entry of Novel Therapies in the Coming Decade | DelveInsight
Chemotherapy-Induced Diarrhea pipeline has a limited number of drugs offering pharma players immense opportunities to explore.
DelveInsight’s ‘Chemotherapy-induced Diarrhea Pipeline Insights‘ report offers comprehensive coverage of the emerging Chemotherapy-induced Diarrhea therapeutics space in different stages of development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents.
The Chemotherapy-induced Diarrhea Pipeline report provides acomprehensive view of the clinical trials, partnerships and collaborations, recent happenings in the space and growth prospects across the Chemotherapy-induced Diarrhea domain.
Some of the key takeaways from the Chemotherapy-induced Diarrhea Pipeline report:
- The Chemotherapy-induced Diarrhea Pipeline report offers a rich analysis of 5+ key players and 5+ key therapies.
- Chemotherapy-induced Diarrhea pipeline comprises emerging therapies in different stages of the clinical phase such as FW-420, Mytesi, OQL051, DP 1038 and others.
- Some of the key companies working to strengthen the Chemotherapy-induced Diarrhea Pipeline are AzuRx BioPharma, Napo Pharmaceuticals, OnQuality Pharmaceuticals, Dauntless Pharmaceuticals, among others.
Request for Sample report to discover more about the therapies set to grab maximum patient pool @ Chemotherapy-induced Diarrhea Emerging Therapies and Forecast
Chemotherapy-induced Diarrhea (CID) is a side-effect of frequently used chemotherapy agents and can lead to delays in treatment and poor quality of life. It is a common problem, especially in patients with advanced cancer and is most often described with fluoropyrimidines (particularly fluorouracil [FU] and capecitabine) and irinotecan.
For more information on emerging drugs, visit Chemotherapy-induced Diarrhea Pipeline Analysis
Chemotherapy-induced Diarrhea Pipeline Drugs Immunostimulants
|FW-420||AzuRx BioPharma||Unknown||MTOR protein inhibitors||Oral/rectal|
|Mytesi||Napo Pharmaceuticals||Phase III||Chloride channel antagonists||Oral|
|DP 1038||Dauntless Pharmaceuticals||Phase II||Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists||Intranasal|
Request for Sample to know more @ Chemotherapy-induced Diarrhea Pipeline Analysis, Key Companies, and Futuristic Trends
The Chemotherapy-induced Diarrhea Pipeline report lays down complete insights into active Chemotherapy-induced Diarrhea pipeline therapies segmented into Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
By Product Type
- Phase I
- Phase II
- Phase III
By Molecule Type
By Route of Administration
By Mechanism of Action
- Chloride channel antagonists
- Growth hormone-releasing hormone inhibitors
- Somatostatin receptor agonists
- MTOR protein inhibitors
- Chloride channel
- Growth hormone-releasing hormone
- Somatostatin receptor
- MTOR protein
Scope of the Report
Key Players: AzuRx BioPharma, Napo Pharmaceuticals, Dauntless Pharmaceuticals, OnQuality Pharmaceuticals and others.
Key Chemotherapy-induced Diarrhea Pipeline Therapies: FW-420, Mytesi, DP 1038, OQL051 and others.
Table of Contents
|2||Chemotherapy-induced Diarrhea Disease Overview|
|3||Chemotherapy-induced Diarrhea Pipeline Outlook|
|5||Chemotherapy-induced Diarrhea Therapeutic Products in Clinical Stage|
|6||Chemotherapy-induced Diarrhea Therapeutic Products in Non-clinical Stage|
|7||Chemotherapy-induced Diarrhea Therapeutics Pipeline Analysis|
|8||Inactive Chemotherapy-induced Diarrhea Pipeline Products|
Visit to know more of what’s covered @ Chemotherapy-induced Diarrhea Emerging Therapies, Treatments and Ongoing Clinical Trials
DelveInsight’s Biliary Tract Cancers (BTCs) – Epidemiology Forecast 2030 report.
DelveInsight’s Chemotherapy-Induced Hearing Loss Market Insights, Epidemiology and Market Forecast – 2030 report.
DelveInsight’s Chronic Heart Failure – Market Insights, Epidemiology and Market Forecast – 2030 report.
DelveInsight’s Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology and Market Forecast – 2030 report.
DelveInsight’s Iron Overload Syndrome Market Insights, Epidemiology and Market Forecast – 2030 report.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News